BERTHE AMELIE IROUNGOU

Dr. BERTHE AMELIE IROUNGOU

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
BIBERTHE AMELIE IROUNGOU
BERTHE AMELIE IROUNGOU
LMLaurette Guignali Mangouka
Laurette Guignali Mangouka
BBBerthold Bivigou-Mboumba
Berthold Bivigou-Mboumba
PMPamela Moussavou-Boundzanga
Pamela Moussavou-Boundzanga
JOJudicaël Obame-Nkoghe
Judicaël Obame-Nkoghe
JNJean Raymond Nzenze
Jean Raymond Nzenze
In December 2019, a novel infectious disease, later named COVID-19, was reported in Wuhan, China.1 COVID-19 is characterized by a clinical presentation ranging from asymptomatic to severe, the latter of which includes cytokine storm.2,3 Older patients or those affected by comorbidities such as cardiovascular diseases, diabetes, or obesity are particularly susceptible to development of severe forms of COVID-19 and are at very high risk for death.4,5 After the initial outbreaks in the Chinese province of Hubei, the COVID-19 pandemic has rapidly spread across the world.6 Despite concerns about the burden of the COVID-19 pandemic in Africa, African countries, with the exception of South Africa, have reported a relatively low number of cases and a low rate of daily increases in infection.7 In Gabon, the first case of COVID-19 was imported from France and reported on March 12, 2020. On March 22, 2020, the Gabonese government established a curfew and partial confinement, including a travel ban on the entire national territory. Three months later, the epidemiologic situation progressed with significant community transmission. By June 15, 2020, 3463 cases of COVID-19 were confirmed, including 23 deaths (a case-fatality rate of 0.66%); by September 2020, 8984 cases of COVID-19 were confirmed, including 55 deaths (a case-fatality rate of 0.61%). This study is focused on the early part of the COVID-19 pandemic in Gabon, when there were initially 2 epidemic foci: Libreville, the national capital on the Atlantic coast, and Franceville in the inner part of the country (eFigure in the Supplement). To date, only 1 retrospective study has been conducted in Gabon8; it highlighted cross-reactivity against SARS-CoV-2 nucleocapsid (N) antigen among 23% of samples collected in 2014. To our knowledge, the clinical and epidemiologic characteristics of patients with COVID-19 in Libreville, Gabon, have not yet been described.

27 August 2022 in IJID Regions
Verified
Journal Article
Open access
BIBERTHE AMELIE IROUNGOU
BERTHE AMELIE IROUNGOU
PBPamela Moussavou Boundzanga
Pamela Moussavou Boundzanga
EEeric elguero
eric elguero
JMJamal Makran
Jamal Makran
BBBerthold Bivigou-Mboumba
Berthold Bivigou-Mboumba
Avelin F. AghokengAvelin F. Aghokeng
Avelin F. Aghokeng
To estimate the seroprevalence of anti-SARS-CoV-2 antibodies in the general population in Gabon, Central Africa. From May to July 2021, a cross-sectional study involving participants recruited in the general population in three districts in Gabon was conducted. Eligible participants who provided written informed consent were tested for anti-SARS-CoV-2 antibodies using a simple rapid diagnostic assay. Overall, 1609 participants were recruited, 1361 (84.6%) from urban sites and 248 (15.4%) from a rural area. The estimated overall seroprevalence was 13.1% (95% CI 11.4–14.8%). The risk of seropositivity increased with age, and the prevalence in the different age groups ranged from 12.9% (8.0–19.4%) in those aged 15–24 years to 23.3% (14.2–34.6%) in those ≥ 65 years old. A higher prevalence was found in the rural population (17.3%; 12.8–22.6%) compared with urban regions (12.3%; 10.6–14.1%). Being a woman was also associated with higher risk of infection (p < 0.001). This seroprevalence survey revealed a moderate seroprevalence in Gabon, illustrating a relatively low rate of circulation of the virus in the country and correlating with low numbers of confirmed cases and deaths reported to date.

1 January 2023 in Archives of Clinical and Medical Case Reports
Verified
Journal Article
Open access
PDF file
BIBERTHE AMELIE IROUNGOU
BERTHE AMELIE IROUNGOU
Larson BoundengaLarson Boundenga
Larson Boundenga
EMEdith Sylvie Manga Manguiya
Edith Sylvie Manga Manguiya
ABAurore Pryslya Bouassa
Aurore Pryslya Bouassa
JNJean Raymond Nzenze
Jean Raymond Nzenze
GMGuignali Laurette Mangouka
Guignali Laurette Mangouka
Despite many Sub-Saharan African countries being relatively unaffected by this pandemic, there is a lack of information on COVID- 19-related biological abnormalities in the region. Therefore, this study aimed to describe the hematological and biochemical abnormalities of COVID-19 patients in Gabon. The study was conducted at the Military Hospital in Libreville, Gabon's capital, and analyzed the hematological and biochemical examination results (including circulating enzymes and blood cell count) of 837 COVID-19 inpatients. The patients were grouped into severe forms admitted to the intensive care unit (n=31, 3.72%), mild symptomatic forms (n=282, 33.7%), and asymptomatic forms (n=524, 62.6%). Over 95% of the patients received hydroxychloroquine and azithromycin. The study found that fatal outcomes (1.4% of the total series, n=12) were significantly associated (P<0.001) with older age (53.1±15.0 years), high CRP levels (378±248 mg/mL), and severe lymphopenia (6.7±6.6%). The median age of the patients was over 41 years, and the only laboratory feature that differentiated symptomatic and asymptomatic cases was an increase in blood levels of LDH (234±88 IU/mL vs. 144±50 mM, P=0.0039). Therefore, the study suggests that CRP, ionic disorders, and LDH could be used as prognostic parameters to assess the severity of illness and classify COVID-19 patients in Sub-Saharan African countries.

9 March 2025 in World Journal of Critical Care Medicine
Verified
Journal Article
Open access
BIBERTHE AMELIE IROUNGOU
BERTHE AMELIE IROUNGOU
AOArnaud Nze O
Arnaud Nze O
HYHelga M Kandet Y
Helga M Kandet Y
NLNeil-Michel Longo-Pendy
Neil-Michel Longo-Pendy
NMNina D Mezogho-Obame
Nina D Mezogho-Obame
GMGuignali L Mangouka
Guignali L Mangouka
BACKGROUND Coronavirus disease 2019 (COVID-19) is strongly associated with an increased risk of thrombotic events, including severe outcomes such as pulmonary embolism. Elevated D-dimer levels are a critical biomarker for assessing this risk. In Gabon, early implementation of anticoagulation therapy and D-dimer testing has been crucial in managing COVID-19. This study hypothesizes that elevated D-dimer levels are linked to increased COVID-19 severity. AIM To determine the impact of D-dimer levels on COVID-19 severity and their role in guiding clinical decisions. METHODS This retrospective study analyzed COVID-19 patients admitted to two hospitals in Gabon between March 2020 and December 2023. The study included patients with confirmed COVID-19 diagnoses and available D-dimer measurements at admission. Data on demographics, clinical outcomes, D-dimer levels, and healthcare costs were collected. COVID-19 severity was classified as non-severe (outpatients) or severe (inpatients). A multivariable logistic regression model was used to assess the relationship between D-dimer levels and disease severity, with adjusted odds ratios (OR) and 95%CI. RESULTS A total of 3004 patients were included, with a mean age of 50.17 years, and the majority were female (53.43%). Elevated D-dimer levels were found in 65.81% of patients, and 57.21% of these experienced severe COVID-19. Univariate analysis showed that patients with elevated D-dimer levels had 3.33 times higher odds of severe COVID-19 (OR = 3.33, 95%CI: 2.84-3.92, P < 0.001), and this association remained significant in the multivariable analysis, adjusted for age, sex, and year of collection. The financial analysis revealed a substantial burden, particularly for uninsured patients. CONCLUSION D-dimer predicts COVID-19 severity and guides treatment, but the high cost of anticoagulant therapy highlights the need for policies ensuring affordable access in resource-limited settings like Gabon.

1 November 2026 in Acta Microbiologica Hellenica
Verified
Journal Article
Open access
PDF file
REROTO ROMULUS ELIORE
ROTO ROMULUS ELIORE
MMMISSONI-MANGA ELSA- LUCE-GUENAELLE MISSONI-MANGA
MISSONI-MANGA ELSA- LUCE-GUENAELLE MISSONI-MANGA
BIBERTHE AMELIE IROUNGOU
BERTHE AMELIE IROUNGOU
MLMangouka Guignali Laurette
Mangouka Guignali Laurette
Infections represent a major public health concern in sub-Saharan Africa, particularly in settings with high HIV prevalence and limited diagnostic capacity. In Gabon, epidemiological data on herpesvirus infections remain fragmented, making it difficult to accurately estimate their burden. This review aimed to assess the prevalence, risk factors, and public health implications of herpesvirus infections in Gabon. A systematic review with narrative synthesis was conducted in accordance with PRISMA 2020 guidelines. Searches were performed using PubMed, Scopus, and Google Scholar for studies published between January 2006 and December 2024. The included studies focused on Gabonese populations and relevant reported epidemiological data. Study selection and data extraction were performed independently by two reviewers. The methodological quality and risk of bias were assessed exclusively using Joanna Briggs Institute (JBI) tools, adapted according to study design. The results show that the most documented infections are Herpes simplex virus type 2 (HSV-2) and Human herpesvirus 8 (HHV-8). HSV-2 is frequently observed among sexually active adults and people living with HIV, while HHV-8 is widely prevalent, particularly in rural settings. Cytomegalovirus (CMV) and Epstein–Barr virus (EBV) are also reported but remain insufficiently studied. Overall, herpesvirus infections remain under-recognized in Gabon, highlighting the need to strengthen epidemiological surveillance and diagnostic capacity.

31 March 2026
Verified
Thesis
Closed access
BIBERTHE AMELIE IROUNGOU
BERTHE AMELIE IROUNGOU
Le syndrome fébrile, une des principales causes de consultation dans les services de pédiatrie en Afrique Subsaharienne, reste dans la majorité des cas liée à une maladie infectieuse (parasitaire, virale, bactérienne). Dans cette thèse, nous avons identifié les agents infectieux non bactériens responsables de la survenue des fièvres chez l'enfant afin de développer des outils moléculaires permettant l'amélioration de la surveillance épidémiologique. Pour ce faire, ce travail est divisé en 2 parties essentielles. Dans la première partie une étude transversale a été réalisée pour analyser l'infection plasmodiale dans une population d'adultes et d'enfants fébriles par microscopie et PCR.Dans la deuxième partie une autre enquête transversale a été conduite pour déterminer les principales causes étiologiques des fièvres non bactériennes chez l'enfant. Sur 203 enfants recrutés, 111 ont été diagnostiqués positifs à P. falciparum, par microscopie et par PCR (ISM). Concomitamment, des cas cliniques d'oreillons et de rougeole ont été observés respectivement sur les 203 enfants fébriles. Le génome complet de la souche responsable d'oreillons a été séquencé et compte 15263 nucléotides. Enfin, le virus responsable de la rougeole a été détecté par PCR et le génotypage a révélé que cette souche était celle qui était responsable de l'épidémie de Libreville.En conclusion, le syndrome fébrile chez l'enfant à Franceville est essentiellement dû aux infections à P. falciparum et Paramyxovirus. Ces résultats montrent que les infections submicroscopiques (ISM)à P. falciparum peuvent non seulement servir de réservoir mais aussi initier une symptomatologie sévère chez l'enfant.